NEW ActiGraft Autologous Wound Matrix – Available Now
ActiGraft is an innovative regenerative wound solution that uses a patient’s own blood to create an autologous whole blood clot tissue
ActiGraft® is an FDA-cleared regenerative wound care solution that enables health care providers to produce—in real time—in vitro blood clots from a patient’s whole blood. Once applied, the blood clot tissue serves as a protective covering, biologic scaffold and wound microenvironment to promote the natural wound healing processes of the body.
ActiGraft is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, diabetic ulcers, and mechanically or surgically-debrided wounds.
> About Actigraft
> Handling and Ease of Use
> Unique Properties
> Clinical Study Overview
AUTOLOGOUS WHOLE BLOOD GRAFT
Actigraft™ is an autologous whole blood clot formed from the patient’s blood. Actigraft™ provides a ﬁbrin scaffold that serves as a protective, provisional extracellular matrix(ECM). It harbors cytokines and growth factors released by the degranulation of activated platelets. The Actigraft™ clot dries out and becomes a protective scab, under which a moist wound environment can be maintained, and tissue remodeling takes place. (1)
The ActiGraft™ System is intended to be used at point-of-care for the safe and rapid preparation of Whole Blood Clot (WBC) gel from a small sample of a patient’s own peripheral blood. Under the supervision of a healthcare professional, the WBC gel produced by the ActiGraft™ System is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers and mechanically or surgically-debrided wounds.
1. Kushnir I, Kushnir A et al. Efficacy and Safety of a Novel Autologous Wound Matrix in the Management of Complicated, Chronic Wounds: A Pilot Study. Wounds 2016;28(9):317-327